Loading
Validation of a 12-gene score for ductal carcinoma in situ, which separated women by their chance of the disease returning in the same breast after surgery without radiotherapy.
In 327 patients from the ECOG E5194 study treated by excision alone, the DCIS score (seven cancer-related and five reference genes, measured with the Oncotype DX assay) was associated with ipsilateral breast events; ten-year risks were 10.6, 26.7 and 25.9 per cent for low, intermediate and high scores.
A gene-activity score can tell some women with DCIS that their chance of recurrence after surgery alone is lower.
Shares Oncotype DX Breast DCIS Score, Gene-expression prognostic assays, Ductal carcinoma in situ (DCIS).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/